Long-Term Androgen-Ablation Causes Increased Resistance to PI3K/Akt Pathway Inhibition in Prostate Cancer Cells

Prostate

Volumn 58, Issue 3, 2004, Pages 259-268

  Pfeil, Karina ^a   Eder, Iris E ^a   Putz, Thomas ^a   Ramoner, Reinhold ^a   Culig, Zoran ^a   Ueberall, Florian ^b   Bartsch, Georg ^a   Klocker, Helmut ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Androgen ablation; Apoptosis; PI3K Akt pathway; Prostate cancer; Survival

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN; CASPASE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEU DIFFERENTIATION FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROPIDIUM IODIDE; PROTEIN KINASE B; SOMATOMEDIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME SUBSTRATE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROGEN ANTAGONISTS; APOPTOSIS; CELL LINE, TUMOR; CHROMONES; DRUG RESISTANCE; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MORPHOLINES; NEUREGULIN-1; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TIME FACTORS;

EID: 0842284577     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10332     Document Type: Article

References (50)

1. Klocker H, Culig Z, Hobisch A, Cato ACB, Bartsch G. Androgen receptor alterations in prostatic carcinoma. Prostate 1994;25:266-273.
2. Carson JP, Kulik G, Weber MJ. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B. Cancer Res 1999;59:1449-1453.
3. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998;58:2720-2723.
4. Wang SI, Parsons R, Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998;4(3):811-815.
5. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JS, Isaacs WB, Sawyers CL. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998;95:5246-5250.
6. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59(17):4291-4296.
7. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Juang C, Coppola D, Nicossla SV, Cheng JQ. Frequent activation of Akt2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000;19(19):2324-2330.
8. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, Roth RA. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999; 274(31):21528-21532.
9. Page C, Huang M, Jin X, Cho K, Lilja J, Reynolds RK, Lin J. Elevated phosphorylation of Akt and Stat 3 in prostate, breast, and cervical cancer cells. Int J Oncol 2000;17(1):23-28.
10. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbalu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL. Increased Akt activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27 kip1 expression. J Biol Chem 2000;275(32):24500-24505.
11. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8(4):1168-1171.
12. O'Gorman DM, McKenna SL, McGahon AJ, Knox KA, Cotter TG. Sensitisation of HL-60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of P13-kinase survival signals. Leukemia 2000;14(4):602-611.
13. Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK. Pro-survival function of Akt/PKB in prostate cancer cells: Relationship with TRAIL resistance. J Biol Chem 2001;276:38361-38365.
14. Beresford SA, Davies MA, Gallick GE, Donato NJ. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PC-3 prostate cancer cells. J Interferon Cytokine Res 2001;21(5):313-322.
15. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999;81(2):242-251.
16. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 1996;93:11802-11807.
17. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibrobalsts. Cancer Res 1991;51:3753-3761.
18. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
19. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 1984;44:3522-3529.
20. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU145). Int J Cancer 1978;21:274-281.
21. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999;96:2110-2115.
22. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002;62(21):6141-6145.
23. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58(2):204-209.
24. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997;57:3660-3663.
25. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275(5308):1943-1947.
26. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997;57:4183-4186.
27. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK, Steck PA. Differential expression of MMAC/PTEN in glioblastoma multiforme: Relationship to localization and prognosis. Cancer Res 1999;59:1820-1824.
28. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16(1):64-67.
29. Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H, Lindboe CF, Fryns JP, Sijmons RH, Woods DG, Mariman EC, Padberg GW, Kremer H. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden diesease. Human Mol Gen 1997;6(8):1383-1387.
30. Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RI, Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997;16(4):333-334.
31. Myers MP, Pass L, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 1998;95(23):13513-13518.
32. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Nati Acad Sci USA 1998;95(26):15587-15591.
33. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mir tsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95(1):29-39.
34. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 1998;273(32):19929-19932.
35. Christian SL, Sims PV, Gold MR. The B cell antigen receptor regulates the transcriptional activator beta-catenin via protein kinase C-mediated inhibition of glycogen synthase kinase-3. J Immunol 2002;169(2):758-769.
36. Manoukian AS, Woodgett JR. Role of glycogen synthase kinase-3 in cancer: Regulation by Wnts and other signaling pathways. Adv Cancer Res 2002;84:203-229.
37. Fang X, Yu SX, Lu Y, Bast RCJ, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA 2000;97(22):11960-11965.
38. Rothermund CA, Kondrikov D, Lin M-F, Vishwanatha JK. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer. Prost Cancer Prost Diseases 2002;5:236-245.
39. Marte BM, Downward J. PKB/Akt: Connecting PI3-kinase to cell survival and beyond. Trends Biochem Sci 1997;22:355-358.
40. Rodriguez-Viciana P, Downward J. Ras activation of PI3 kinase and Akt. Methods Enzymol 2001;333:37-44.
41. Marshall CJ. Ras effectors. Curr Opin Cell Biol 1996;8(2):197-204.
42. Filippa N, Sable CL, Filloux C, Hemmings BA, van Obberghen E. Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase. Mol Cell Biol 1999;19(7):4989-5000.
43. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002;1(11):913-922.
44. Seki M, Iwakawa J, Cheng H, Cheng PW. p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. Hum Gene Ther 2002;13(6):761-773.
45. Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD, Gallick GE. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 2002;8(6):1904-1914.
46. Chinni SR, Sarkar FH. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin Cancer Res 2002;8:1228-1236.
47. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998;10:262-267.
48. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001;20:6073-6083.
49. Yuan XJ, Whang YE. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 2002;21(2):319-327.
50. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001;276(14):10767-10774.